Category 3 - THERAPEUTIC PROCEDURES
16055 - Additional Information
Item Start Date:
01-Jul-2025
Description Updated:
01-Jul-2025
Schedule Fee Updated:
01-Jul-2025
Group
T3 - Therapeutic Nuclear Medicine
Subgroup
2 - Theranostics
Administration of Lutetium 177 PSMA, followed within 36 hours by whole body Lu-PSMA SPECT, for treatment of a patient with metastatic castrate resistant prostate cancer, if:
(a) a service to which item 16050 applies has been provided; and
(b) the patient has not developed disease progression while receiving Lutetium 177 PSMA for this condition.
Applicable once per cycle, up to a maximum of 4 cycles in the continuing treatment phase.
Fee: $8,000.00 Benefit: 75% = $6,000.00 85% = $7,897.60
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change